GLPG-3970

N/A

Report date: 2026/04/23 20:00:25
NME

Base Information

Drug NameGLPG-3970
Drug Alias NameGLPG-3970
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase SIK2 inhibitorsSalt-inducible kinase 3 inhibitors
TargetsSerine/threonine-protein kinase SIK2Salt-inducible kinase 3
Therapy Area/IndicationsLupus Erythematosus, SystemicColitis, UlcerativeSjogren's Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesUkraine +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGalapagos Nv
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncGalapagos Nv
Inactive CompaniesN/A
Active IndicationsColitis, Ulcerative
Inactive IndicationsLupus Erythematosus, SystemicSjogren's SyndromeArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A